What the HeartMate 3 ® Device Tells Us About the Future

Overview

About this study

The purpose of this study is to evaluate the effectiveness of HeartMate 3 ® dLVAD normal and abnormal pump operations data on clinical practice applications when utilizing downloadable pump data analyses at several time points following implantation: discharge from the intensive care unit (ICU), +/- 3 days of discharge from the hospital (over a week post implant), 3 months post dLVAD, 6 months post dLVAD, and 12 months post dLVAD.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

18 years of age or older.
Scheduled Heartmate 3 ® dLVAD implantation.

Exclusion Critieria:

< 18 years of age.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/16/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Andrew Rosenbaum, M.D.	Open for enrollment	Contact information: Heart Failure Research Team (507) 422-6190

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Andrew Rosenbaum, M.D.

Open for enrollment

Contact information:

Heart Failure Research Team

(507) 422-6190

More information

Publications

Publications are currently not available

Clinical Trials